1. ALLA AKTIER
  2. NYHETER
  3. ZICCUM

Ziccum

Nyheter Ziccum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6th

Join Ziccum CEO Ann Gidner on Tuesday 6 February for ‘Invest live’ as she presents Ziccum’s unique technology for biopharmaceuticals and its ground-breaking new mRNA data at a live digital event with Investor Target. Participants may post questions ahead of the event and watch live at the link below.

At 12.00 noon on Tuesday February 6 Ziccum CEO Ann Gidner will present the Company at “Invest Live” hosted by Investor Target analyst Kaarlo Airaxin. The event will take place in Swedish.

Ann will cover Ziccum’s formulating and drying technology LaminarPace, how it can turn delicate vaccines and biologics including mNRA into robust thermostable dry powders, the market opportunity for this, and the Company’s outstanding performance over the last 18 months.

Mail your questions ahead of the event here: kaarlo.airaxin@investortarget.se

Watch the event live here: https://youtube.com/live/qldbpqBV8Js?feature=share

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75
 
Ziccum’s Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on https://eucaps.com/ziccum

About Ziccum

Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6th

Datum 2024-02-03, kl 12:20
Källa MFN
Bifogade filer
Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6th